1	Coralmycin derivatives with potent anti-Gram negative activity produced by
2	the myxobacteria Corallococcus coralloides M23
3	Bo-Min Kim, <sup>1,2, #</sup> Nguyen Van Minh, <sup>1,3,#</sup> Ha-Yung Choi, <sup>1,2</sup> and Won-Gon Kim <sup>1, 2,*</sup>
4	<sup>1</sup> Superbacteria Research Center, Korea Research Institute of Bioscience and Biotechnology,
5	Yusong, Daejeon 305-806, Korea
6 7	<sup>2</sup> Department of Bio-Molecular Science, KRIBB School of Bioscience, Korea University of Science and Technology (UST), Yusong, Daejeon 305-806, Republic of Korea
8	<sup>3</sup> College of Pharmacy, Chungnam National University, Daejeon 34134, Republic of Korea.
9	
10	<sup>#</sup> These authors contributed equally.
11	* Correspondence: wgkim@kribb.re.kr; Tel.: +82-42-860-4298

Fermentation. Fermentation was carried out in CYS medium containing 0.5% casitone, 0.1% 13 yeast extract, 0.3% soluble starch, 0.1% MgSO<sub>4</sub>·7H<sub>2</sub>O, 0.05% CaCl<sub>2</sub>, 50 mM 4-(2-hydroxyethyl)-14 1-piperazineethanesulfonic acid (HEPES), 0.4% trace element solution, and 0.5 µg/mL 15 16 cyanocobalamin. The trace element solution contained 100 mg/L MnCl<sub>2</sub>·4H<sub>2</sub>O, 20 mg/L CoCl<sub>2</sub>, 10 mg/L CuSO<sub>4</sub>, 10 mg/L Na<sub>2</sub>MoO<sub>4</sub>· 2H<sub>2</sub>O, 20 mg/L ZnCl<sub>2</sub>, 5 mg/L LiCl, 5 mg/L SnCl<sub>2</sub>· 2H<sub>2</sub>O, 10 17 mg/L H<sub>3</sub>BO<sub>3</sub>, 20 mg/L KBr, 20 mg/L KI, and 8 g/L EDTA Na-Fe<sup>3+</sup> salt (trihydratepiece of agar 18 from t). The mature plate culture of the producing strain was inoculated into a 500-mL Erlenmeyer 19 20 flask containing 100 mL of sterile seed liquid medium with the above composition and cultured on a rotary shaker (150 rpm) at 28 °C for 3 days. The 300 mL of the seed culture was transferred 21 22 into a 5-L Jar fermenter containing 2.5 L of the above medium containing 100 g of Amberlite XAD16 (Sigma, USA), and then cultivated at 28 °C for 2 days with an aeration rate of 0.4 v/min 23 24 and agitation rate of 350 rpm. The resultant 3 L culture was transferred into a 50-L fermenter 25 containing 30 L of the above medium containing 1.2 kg of Amberlite XAD16, and then cultivated at 28 °C for 3 days with an aeration rate of 0.4 v/min and agitation rate of 200 rpm. The resultant 26 30 L culture was transferred into a 500-L fermenter containing 300 L of the above medium 27 containing 12 kg of Amberlite XAD16, and then cultivated at 28 °C for 3 days with an aeration 28 rate of 0.4 v/min and agitation rate of 100 rpm. The resultant 300L culture was transferred into a 29 30 5000-L fermenter containing 3000 L of the above medium containing 120 kg of Amberlite XAD16, and then cultivated at 28 °C for 6 days with an aeration rate of 0.4 v/min and agitation rate of 70 31 rpm. 32

- 34
- 35
- 36
- 37
- 38

Table S1. Antibacterial activities of 4–7 and related compour	nds.
---	------

Test organisms	MIC (µg/mL)					
Test organisms	4	5	6	7	10	Cip*
Staphylococcus aureus RN 4220	>32	>32	>32	>32	>32	0.125
MRSA CCARM 3167	>32	>32	>32	>32	>32	4
MRSA CCARM 3506	>32	>32	>32	>32	>32	2
QRSA CCARM 3505	>32	>32	>32	>32	>32	128
QRSA CCARM 3519	>32	>32	>32	>32	>32	128
Streptococcus pneumonia KCTC 5412	>32	>32	>32	>32	>32	0.25
Enterococcus faecalis KCTC 5191	>32	>32	>32	>32	>32	0.5
Acinetobacter baumannii KCTC 2508	>32	>32	>32	>32	>32	0.25
E. coli CCARM 1356	>32	>32	>32	>32	>32	64
E. coli KCTC 1682	>32	>32	>32	>32	>32	0.06
Pseudomonas aeruginosa KCTC 2004	>32	>32	>32	>32	>32	0.03
Klebsiella pneumoniae KCTC 22057	>32	>32	>32	>32	>32	0.015

\*Ciprofloxacin

## 47 Legends for Figures

48	Figure S1. Positive HRESIMS spectrum of cystobactamid 891-2 (8).	7
49	Figure S2. <sup>1</sup> H-NMR spectrum of cystobactamid 891-2 (8) measured in DMSO-d <sub>6</sub> at 500 MHz.	8
50	Figure S3. HMQC spectrum of cystobactamid 891-2 (8) measured in DMSO-d <sub>6</sub> at 500 MHz.	9
51	Figure S4. HMBC spectrum of cystobactamid 891-2 (8) measured in DMSO-d <sub>6</sub> at 500 MHz.	10
52	Figure S5. Positive HRESIMS spectrum of cystobactamid 905-2 (9).	11
53	Figure S6. <sup>1</sup> H-NMR spectrum of cystobactamid 905-2 (9) measured in DMSO-d <sub>6</sub> at 500 MHz.	12
54	Figure S7. HMQC spectrum of cystobactamid 905-2 (9) measured in DMSO-d <sub>6</sub> at 500 MHz.	13
55	Figure S8. HMBC spectrum of cystobactamid 905-2 (9) measured in DMSO-d <sub>6</sub> at 500 MHz.	14
56	Figure S9. CD spectra of coralmycins C (1), D (2), and E (3), and cystobactamids 891-2 (8) and 905-2 (9).	15
57	Figure S10. HPLC profiles of coralmycins C (1) and B (13). A) compound 1; B) compound 13; C) mixture of	<b>1</b> and
58	<u>13 at ratio of 1:1.</u>	16
59	Figure S11. Positive HRESIMS spectrum of coralmycin C (1).	17
60	Figure S12. <sup>1</sup> H-NMR spectrum of coralmycin C (1) measured in DMSO-d <sub>6</sub> at 500 MHz.	18
61	Figure S13. COSY spectrum of coralmycin C (1) measured in DMSO-d <sub>6</sub> at 500 MHz.	19
62	Figure S14. HMQC spectrum of coralmycin C (1) measured in DMSO-d <sub>6</sub> at 500 MHz.	20
63	Figure S15. HMBC spectrum of coralmycin C (1) measured in DMSO-d <sub>6</sub> at 500 MHz.	21
64	Figure S16. HECADE spectrum of coralmycin C (1) measured in DMSO-d <sub>6</sub> at 700MHz.	23
65	Figure S17. NOESY spectrum of coralmycin C (1) measured in DMSO-d <sub>6</sub> at 500 MHz.	233
66	Figure S18. The NOE differential spectra of coralmycin C (1) measured in DMSO-d <sub>6</sub> at 700MHz	24
67	Figure S19. NOE correlations of coralmycin C (1) in comparison with cystobactamid 919-2 and coralmycin B	25
68	Figure S20. Positive HRESIMS spectrum of coralmycin D (2).	266
69	Figure S21. <sup>1</sup> H-NMR spectrum of coralmycin D (2) measured in DMSO-d <sub>6</sub> at 500 MHz.	277
70	Figure S22. COSY spectrum of coralmycin D (2) measured in DMSO-d <sub>6</sub> at 500 MHz.	288
71	Figure S23. HMQC spectrum of coralmycin D (2) measured in DMSO-d <sub>6</sub> at 500 MHz.	299
72	Figure S24. HMBC spectrum of coralmycin D (2) measured in DMSO-d <sub>6</sub> at 500 MHz.	30
73	Figure S25. HETLOC spectrum of coralmycin D (2) measured in DMSO-d6 at 900MHz.	31
74	Figure S26. NOESY spectrum of coralmycin D (2) measured in DMSO-d <sub>6</sub> at 500 MHz.	32
75	Figure S27. The NOE differential spectra of coralmycin D (2) measured in DMSO-d6 at 800MHz.	33
76	Figure S28. Positive HRESIMS spectrum of coralmycin E (3).	34
77	Figure S29. <sup>1</sup> H-NMR spectrum of coralmycin E (3) measured in DMSO-d <sub>6</sub> at 500 MHz.	35
78	Figure S30. <sup>13</sup> C-NMR spectrum of coralmycin E (3) measured in DMSO-d <sub>6</sub> at 500 MHz.	366

79	Figure S31. COSY spectrum of coralmycin E (3) measured in DMSO-d <sub>6</sub> at 500 MHz.	37
80	Figure S32. HMQC spectrum of coralmycin E (3) measured in DMSO-d <sub>6</sub> at 500 MHz.	
81	Figure S33. HMBC spectrum of coralmycin E (3) measured in DMSO-d <sub>6</sub> at 500 MHz.	39
82	Figure S34. HECADE spectrum of coralmycin E (3) measured in DMSO-d <sub>6</sub> at 700 MHz.	40
83	Figure S35. NOESY spectrum of coralmycin E (3) measured in DMSO-d <sub>6</sub> at 500 MHz.	41
84	Figure S36. The NOE differential spectra of coralmycin E (3) measured in DMSO-d6 at 800MHz.	42
85	Figure S37. Positive and negative ESIMS spectrum of cystobactamid 507 (10).	43
86	Figure S38. <sup>1</sup> H NMR spectrum of cystobactamid 507 (10) measured in CD3OD at 700 MHz.	44
87	Figure S39. <sup>13</sup> C-NMR spectrum of cystobactamid 507 (10) measured in CD3OD at 700 MHz.	45
88	Figure S40. HMBC spectrum of cystobactamid 507 (10) measured in CD3OD at 900 MHz.	46
89	Figure S41. Positive HRESIMS spectrum of coralmycin F (4).	47
90	Figure S42. <sup>1</sup> H NMR spectrum of coralmycin F (4) measured in CD <sub>3</sub> OD at 800 MHz.	48
91	Figure S43. HMQC spectrum of coralmycin F (4) measured in CD <sub>3</sub> OD at 500 MHz.	49
92	Figure S44. HMBC spectrum of coralmycin F (4) measured in CD <sub>3</sub> OD at 800 MHz.	50
93	Figure S45. Positive HRESIMS spectrum of coralmycin G (5).	51
94	Figure S46. <sup>1</sup> H NMR spectrum of coralmycin G (5) measured in DMSO-d <sub>6</sub> at 800 MHz.	52
95	Figure S47. HMQC spectrum of coralmycin G (5) measured in DMSO-d <sub>6</sub> at 800 MHz.	53
96	Figure S48. HMBC spectrum of coralmycin G (5) measured in DMSO-d <sub>6</sub> at 800 MHz.	54
97	Figure S49. Positive HRESIMS spectrum of coralmycin H (6).	55
98	Figure S50. <sup>1</sup> H NMR spectrum of coralmycin H (6) measured in DMSO-d <sub>6</sub> at 800 MHz.	56
99	Figure S51. HMQC spectrum of coralmycin H (6) measured in DMSO-d <sub>6</sub> at 800 MHz.	57
100	Figure S52. HMBC spectrum of coralmycin H (6) measured in DMSO-d <sub>6</sub> at 800 MHz.	58
101	Figure S53. Positive HRESIMS spectrum of coralmycin I (7).	59
102	Figure S54. <sup>1</sup> H NMR spectrum of coralmycin I (7) measured in DMSO-d <sub>6</sub> at 500 MHz.	60
103	Figure S55. HMQC spectrum of coralmycin I (7) measured in DMSO-d <sub>6</sub> at 500 MHz.	61
104	Figure S56. Expansion of HMQC spectrum of coralmycin I (7).	62
105	Figure S57. HMBC spectrum of coralmycin I (7) measured in DMSO-d <sub>6</sub> at 500 MHz.	63
106	Figure S58. Expansion of HMBC spectrum of coralmycin I (7).	64
107	<b>Figure S59.</b> Agarose gels of E. coli gyrase supercoiling reactions inhibited by coralmycins (C (1), D (2), E (3),	<u>F (4),</u>
108 109	A (12), and B (13)) and cystobactamids (891-2 (8), 905-2 (9), 919-2 (11), and 507 (10)). (-), reaction without gyrase; (+), standard reaction in presence of 5% DMSO; rel, relaxed plasmid; SC, supercoiled plasmid	<u>. colı</u> 5
110	<b>Figure S60</b> HPLC profile of coralmycins (C (1) D (2) F (3) A (12) and B (13)) and cystobactamide (891)	2 (8)
111	905-2 ( <b>9</b> ), and 919-2 ( <b>11</b> )).	<u>- (6),</u> 66

**Figure S61.** HPLC profile of coralmycins (F (4), G (5), H (6), and I (7)) and cystobactamid 507 (10). .....67



**Figure S1.** Positive HRESIMS spectrum of cystobactamid 891-2 (8).





**Figure S3.** HMQC spectrum of cystobactamid 891-2 (8) measured in DMSO-*d*<sub>6</sub> at 500 MHz.



Figure S4. HMBC spectrum of cystobactamid 891-2 (8) measured in DMSO-*d*<sub>6</sub> at 500 MHz. 



**Figure S5.** Positive HRESIMS spectrum of cystobactamid 905-2 (9).







**Figure S8.** HMBC spectrum of cystobactamid 905-2 (9) measured in DMSO-*d*<sub>6</sub> at 500 MHz.





**Figure S10.** HPLC profiles of coralmycins C (1) and B (13). HPLC condition: column YMC C18, S-4  $\mu$ m, 4.6 x 250 mm; eluent: isocratic 50% CH<sub>3</sub>CN in H<sub>2</sub>O (v/v), containing 0.01% TFA at flow rate of 0.8 mL/min with PDA detector Waters 996. A) compound 1; B) compound 13; C) mixture of 1 and 13 at ratio of 1:1.





**Figure S11.** Positive HRESIMS spectrum of coralmycin C (1).





Figure S13. COSY spectrum of coralmycin C (1) measured in DMSO-d<sub>6</sub> at 500 MHz. 



**Figure S14.** HMQC spectrum of coralmycin C (1) measured in DMSO-d<sub>6</sub> at 500 MHz.











Figure S19. NOE correlations of coralmycin C (1) in comparison with cystobactamid 919-2 (11)
 and coralmycin B (13).



Figure S20. Positive HRESIMS spectrum of coralmycin D (2).









Figure S24. HMBC spectrum of coralmycin D (2) measured in DMSO-*d*<sub>6</sub> at 500 MHz.













Figure S27. The NOE differential spectra of coralmycin D (2) measured in DMSO-*d*<sub>6</sub> at 800 MHz.



**Figure S28.** Positive HRESIMS spectrum of coralmycin E (3).







Figure S31. COSY spectrum of coralmycin E (3) measured in DMSO- $d_6$  at 500 MHz.











Figure S36. The NOE differential spectra of coralmycin E (3) measured in DMSO- $d_6$  at 800 MHz.



Figure S37. Positive and negative ESIMS spectrum of cystobactamid 507 (10).







**Figure S40.** HMBC spectrum of cystobactamid 507 (10) measured in CD<sub>3</sub>OD at 800 MHz.



**Figure S41.** Positive HRESIMS spectrum of coralmycin F (4).





**Figure S43.** HMQC spectrum of coralmycin F (4) measured in CD<sub>3</sub>OD at 500 MHz.



**Figure S44.** HMBC spectrum of coralmycin F (4) measured in CD<sub>3</sub>OD at 800 MHz.



**Figure S45.** Positive HRESIMS spectrum of coralmycin G (5).



![](_page_52_Figure_0.jpeg)

**Figure S47.** HMQC spectrum of coralmycin G (**5**) measured in DMSO-*d*<sub>6</sub> at 800 MHz.

![](_page_53_Figure_0.jpeg)

**Figure S48.** HMBC spectrum of coralmycin G (**5**) measured in DMSO-*d*<sub>6</sub> at 800 MHz.

![](_page_54_Figure_0.jpeg)

**Figure S49.** Positive HRESIMS spectrum of coralmycin H (6).

![](_page_55_Figure_0.jpeg)

![](_page_56_Figure_0.jpeg)

**Figure S51.** HMQC spectrum of coralmycin H (6) measured in DMSO-*d*<sub>6</sub> at 800 MHz.

![](_page_57_Figure_0.jpeg)

**Figure S52** HMBC spectrum of coralmycin H (6) measured in DMSO-*d*<sub>6</sub> at 800 MHz.

![](_page_58_Figure_0.jpeg)

**Figure S53.** Positive HRESIMS spectrum of coralmycin I (7).

![](_page_59_Figure_0.jpeg)

![](_page_60_Figure_0.jpeg)

![](_page_61_Figure_0.jpeg)

**Figure S56.** Expansion of HMQC spectrum of coralmycin I (7).

![](_page_62_Figure_0.jpeg)

**Figure S57.** HMBC spectrum of coralmycin I (7) measured in DMSO- $d_6$  at 500 MHz.

![](_page_63_Figure_0.jpeg)

![](_page_64_Figure_1.jpeg)

Figure S59. Agarose gels of *E. coli* gyrase supercoiling reactions inhibited by coralmycins (C (1), D (2), E (3), F (4), A (12), and B (13)) and cystobactamids (891-2 (8), 905-2 (9), 919-2 (11), and 507 (10)). (-), reaction without E. coli gyrase; (+), standard reaction in presence of 5% DMSO; rel, relaxed plasmid; SC, supercoiled plasmid. 

![](_page_65_Figure_0.jpeg)

![](_page_65_Figure_3.jpeg)

![](_page_65_Figure_4.jpeg)

Figure S60. HPLC profiles of coralmycins (C (1), D (2), E (3), A (12), and B (13)) and
cystobactamids (891-2 (8), 905-2 (9), and 919-2 (11)). J'sphere ODS-H80 (150x4.6 mm I.D), 50%
ACN + 0.01% TFA, 0.8 mL/min, 25°C

![](_page_66_Figure_0.jpeg)

434 Figure S61. HPLC profiles of coralmycins F (4), G (5), H (6), and I (7), and cystobactamid 507

435 (**10**). J'sphere ODS-H80 (150x4.6 mm I.D), 50% ACN + 0.01% TFA, 0.8 mL/min, 25°C.

436